NEVVI Medicare utilization intelligence

← back

Provider profile

GIBSON, DONNA MSNED, RN, FNP-C

Nurse Practitioner · NPI 1730344458 · ASHEVILLE, NC

1
Groups
16
Codes · 2024
3,581
Disclosed services

GIBSON, DONNA is a Nurse Practitioner in ASHEVILLE, NC, a member of 1 medical group, who billed 16 distinct codes to Medicare Part B in 2024.

Groups: AMERICAN ONCOLOGY PARTNERS PA (FORT WAYNE, IN)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

3,581
disclosed services
16
codes billed to Medicare Part B
Prior year · CY2023 1,277 disclosed services

This provider's disclosed Medicare payments across all codes were premium in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1437 Injection, ferric derisomaltose, 10 mg premiumpremium premiumpremium
J1100 Injection, dexamethasone sodium phosphate, 1 mg premiumpremium premiumpremium
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count premiumpremium premiumpremium
36415 Insertion of needle into vein for collection of blood sample premiumpremium premiumpremium
Q5130 Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg premiumpremium premiumpremium
96413 Administration of chemotherapy into vein, 1 hour or less premiumpremium premiumpremium
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more premiumpremium premiumpremium
96372 Injection of drug or substance under skin or into muscle premiumpremium premiumpremium
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more premiumpremium premiumpremium
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less premiumpremium premiumpremium
96375 Injection of additional new drug or substance into vein premiumpremium premiumpremium
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less premiumpremium premiumpremium
96523 Irrigation of implanted venous access drug delivery device premiumpremium premiumpremium
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more premiumpremium premiumpremium
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg premiumpremium premiumpremium
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's premiumpremium premiumpremium

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.